

U.S.S.N. 09/942,959
Osbakken *et al.*
PRELIMINARY AMENDMENT

74. (New) The method of claim 67, wherein the pharmaceutical composition further comprises a second agent, wherein the second agent is selected from the group consisting of an anti-histamine, a mast cell stabilizer, a non-antibiotic anti-microbial agent, an anti-leukotriene, an anti-viral, an antiseptic, a non-steroidal anti-inflammatory, a combination of at least two antibiotics, an agent for treating nasal polyps, an anticholinergic agent and combinations thereof

75. (New) The method of claim 74, wherein the agent for treating allergies is an anti-histamine.

76. (New) The method of claim 75, wherein the anti-histamine is selected from the group consisting of ethanolamine, ethylenediamine, alkylamine, phenothiazine, piperazine, cyproheptidine, azatadine, diphenylpyraline, ketotifen, terfenadine, fexofenadine, asternizole, and phenindamine.

77. (New) The method of claim 76, wherein the ethanolamine is selected from the group consisting of diphenhydramine, carbinoxamine, clemastine, phenytoloxamine, doxylamine, dimenhydrinate, and bromodiphenhydramine hydrochloride.

78. (New) The method of claim 74, wherein the second agent is a mast cell stabilizer.

79. (New) The method of claim 78, wherein the mast cell stabilizer is selected from the group consisting of cromolyn or nedocromil sodium.

80. (New) The method of claim 74, wherein the second agent is a non-antibiotic anti-microbial agent.

81. (New) The method of claim 80, wherein the non-antibiotic anti-microbial agent is taurolidine.

82. (New) The method of claim 74, wherein the second agent is an anti-leukotriene.

U.S.S.N. 09/942,959
Osbakken *et al.*
PRELIMINARY AMENDMENT

83. (New) The method of claim 82, wherein the anti-leukotriene is selected from the group consisting of zafirlukast, montelukast, pranlukast, iralukast, and pobilukast.

84. (New) The method of claim 74, wherein the second agent is a non-steroidal anti-inflammatory.

85. (New) The composition of claim 84, wherein the non-steroidal anti-inflammatory is selected from the group consisting of fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, ketorolac, nabumetone, sulindac tolmetin meclofenamate, mefenamic acid, piroxicam and suprofen.

86. (New) The method of claim 74, wherein the second agent is a non-antibiotic anti-microbial agent., wherein the at least two antibiotics are selected from the group consisting of penicillins, cephalosporins, macrolides, ketolides, sulfonamides, quinolones, aminoglycosides, beta lactam antibiotics, and linezolid.

87. (New) The method of claim 67, wherein the surfactant is a polysorbate.

88. (New) The method of claim 67, wherein the surface tension is about 10 to about 70 dynes/cm.

89. (New) The method of claim 67, wherein the surface tension is about 20 to about 60 dynes/cm.

90. (New) The method of claim 67, wherein the surface tension is about 30 to about 50 dynes/cm.

91. (New) The method of claim 67, wherein the composition is formulated for administration via a nebulizer.

92. (New) The method of claim 67, wherein the composition has an osmolality of about 150 mOsm/kg to about 880 mOsm/kg.